Tandem upgraded, Insulet downgraded at Stifel on market for tubeless insulin pumps
Stifel upgraded Tandem Diabetes Care (TNDM) to Buy and downgraded Insulet (PODD) to Hold, based on survey results about the tubeless insulin pump market.
TANDEM DIABETES CARE INC
Tandem Diabetes Care designs, develops and commercializes insulin delivery systems and diabetes technology for people with insulin-dependent diabetes. Its pump platforms include t:slim X2 and Tandem Mobi, which can be used with continuous glucose monitoring sensors as automated insulin delivery systems powered by Control-IQ+ technology. Tandem also sells single-use pump supplies, including insulin cartridges and infusion sets. Its software and data offerings include the Tandem Device Updater, the Tandem Source web platform for therapy data, and the Sugarmate mobile app. Tandem makes money by selling pumps and replacement supplies, and offers software updates to in-warranty customers at no cost. Its technology is available in more than 25 countries. In the United States and Canada, Tandem uses direct sales, customer support and clinical teams, with independent distributors handling order fulfillment. Its pumps are assembled, tested and packaged at its facilities in San Diego, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Stifel upgraded Tandem Diabetes Care (TNDM) to Buy and downgraded Insulet (PODD) to Hold, based on survey results about the tubeless insulin pump market.
Stifel upgraded Tandem Diabetes Care (TNDM) to Buy with a $26 price target, citing product pipeline and undervaluation. The stock trades at $17.06, suggesting 50% upside. The company reported Q3 revenue of $284M, beating estimates, and received FDA clearance for its Tandem Mobi device. Mizuho raised its price target to $20.
Windward Bio Group (WWB) surged 40% after a $225M IPO and $50M private placement. LifeMD (LFMD) gained 30% on Q3 results and partnerships. SS Innovations (SSII) rose 20% with new leadership. Tandem Diabetes (TNDM) advanced 14% on FDA clearance for a tubeless insulin pump.
Over the past 7 days, AlphAI's AI scored 17 news stories mentioning TNDM (TANDEM DIABETES CARE INC). Coverage has skewed bullish: 17 bullish, 0 neutral, and 0 bearish.
Recent TNDM coverage spans financial news, market movers and regulation.
In the last 30 days, TNDM insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($33K). The most active reporter was TWOMEY CHRISTOPHER J with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Upgrade bias likely supports near-term sentiment for TNDM as investors price improved demand outlook from the survey.
The upgrade and regulatory clearance are likely to lift the stock as investors price in higher growth expectations.
FDA clearance for a novel insulin pump.
Clearance removes a key product gap and opens a new commercial launch, driving strong buying pressure.
Clearance removes regulatory barrier, enabling commercial launch and potential market share gains.
AlphAI scores every news story that mentions TNDM with an AI model for sentiment and relevance, and aggregates insider trades from TANDEM DIABETES CARE INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel upgraded Tandem Diabetes Care (TNDM) to Buy and downgraded Insulet (PODD) to Hold, based on survey results about the tubeless insulin pump market.
Stifel upgraded Tandem Diabetes Care (TNDM) to Buy with a $26 price target, citing product pipeline and undervaluation. The stock trades at $17.06, suggesting 50% upside. The company reported Q3 revenue of $284M, beating estimates, and received FDA clearance for its Tandem Mobi device. Mizuho raised its price target to $20.
Windward Bio Group (WWB) surged 40% after a $225M IPO and $50M private placement. LifeMD (LFMD) gained 30% on Q3 results and partnerships. SS Innovations (SSII) rose 20% with new leadership. Tandem Diabetes (TNDM) advanced 14% on FDA clearance for a tubeless insulin pump.
Tandem Diabetes Care (TNDM) stock rose 14.2% after FDA clearance for its tubeless insulin delivery system, with a 2027 U.S. launch planned. Mizuho raised its price target to $20. Q3 2026 revenue was $283.7M, up 13.8% YoY, beating estimates. The move was driven by company-specific news, not broader market trends.
TANDEM DIABETES CARE INC (TNDM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 12, 2026, Tandem Diabetes Care, Inc. (the “Company”) received 510(k) clearance from the U.S. Food and Drug Administration for Tandem Mobi, the world’s first and only tubeless automated insulin delivery system with up to 7 days of wear (1) . A n
Tandem Diabetes Care (TNDM) received Health Canada approval for its t:slim X2 insulin pump, adding compatibility with Abbott’s FreeStyle Libre 3 Plus sensor and expanding use to type 2 diabetes and pregnancy in type 1 diabetes. The features are expected to launch in Q2 2027, broadening the pump's market.
TNDM reported Q3 2026 revenue of $283.7M, beating estimates by 7.6%. EPS and EBITDA also exceeded expectations. The company reconfirmed its full-year revenue guidance of $1.08B. Key initiatives include a gradual pharmacy channel transition, international expansion, and new product launches. CEO John Sheridan will retire, with Jeannette Bankes succeeding him.
Tandem Diabetes Care forecasts 2026 sales of $1.065B to $1.085B, with adjusted EBITDA margin of 5% to 6% and gross margin of 56% to 57%. CEO John Sheridan plans to retire by year-end 2026, with Jeannette Bankes part of the leadership transition.
Barclays kept its Equal-Weight rating on Tandem Diabetes Care but increased its price target to $20 from $18, suggesting an 11.2% upside from the Nov 5 close of $17.99.
Wells Fargo kept Tandem Diabetes Care's rating at Overweight but reduced its price target to $25 from $27, a 7.4% cut. This implies a 39.0% upside from the Nov 5 close of $17.99.